Search research articles
Contact Us
Filters
Showing results (31-40 of 95) with videos related to
Page
of 10
Sort By:
International Journal of Cancer
|
February 15, 2018
Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model
Sifeng Qu, Hui Xue, Xin Dong, et al.
Oncotarget
|
July 30, 2014
The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis
Sze Ue Iris Luk, Hui Xue, Hongwei Cheng, et al.
Genome Research
|
August 4, 2017
HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology
Raunak Shrestha, Ermin Hodzic, Thomas Sauerwald, et al.
Plos One
|
July 19, 2014
Systematic identification and characterization of RNA editing in prostate tumors
Fan Mo, Alexander W Wyatt, Yue Sun, et al.
British Journal of Cancer
|
January 31, 2018
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
Sifeng Qu, Xinpei Ci, Hui Xue, et al.
Cold Spring Harbor Molecular Case Studies
|
September 3, 2017
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents
David C Wilkes, Verena Sailer, Hui Xue, et al.
The Prostate
|
August 28, 2019
Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men
Ye Feng, Weerachai Jaratlerdsiri, Sean M Patrick, et al.
Cells
|
June 10, 2020
Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development
Xinpei Ci, Jun Hao, Xin Dong, et al.
Bioinformatics (Oxford, England)
|
December 22, 2017
Computational identification of micro-structural variations and their proteogenomic consequences in cancer
Yen-Yi Lin, Alexander Gawronski, Faraz Hach, et al.
Clinical Epigenetics
|
April 11, 2015
Polycomb-mediated silencing in neuroendocrine prostate cancer
Pier-Luc Clermont, Dong Lin, Francesco Crea, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 95) with videos related to
Sort By:
Page
of 10
International Journal of Cancer
|
February 15, 2018
Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model
Sifeng Qu, Hui Xue, Xin Dong, et al.
Oncotarget
|
July 30, 2014
The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis
Sze Ue Iris Luk, Hui Xue, Hongwei Cheng, et al.
Genome Research
|
August 4, 2017
HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology
Raunak Shrestha, Ermin Hodzic, Thomas Sauerwald, et al.
Plos One
|
July 19, 2014
Systematic identification and characterization of RNA editing in prostate tumors
Fan Mo, Alexander W Wyatt, Yue Sun, et al.
British Journal of Cancer
|
January 31, 2018
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
Sifeng Qu, Xinpei Ci, Hui Xue, et al.
Cold Spring Harbor Molecular Case Studies
|
September 3, 2017
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents
David C Wilkes, Verena Sailer, Hui Xue, et al.
The Prostate
|
August 28, 2019
Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men
Ye Feng, Weerachai Jaratlerdsiri, Sean M Patrick, et al.
Cells
|
June 10, 2020
Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development
Xinpei Ci, Jun Hao, Xin Dong, et al.
Bioinformatics (Oxford, England)
|
December 22, 2017
Computational identification of micro-structural variations and their proteogenomic consequences in cancer
Yen-Yi Lin, Alexander Gawronski, Faraz Hach, et al.
Clinical Epigenetics
|
April 11, 2015
Polycomb-mediated silencing in neuroendocrine prostate cancer
Pier-Luc Clermont, Dong Lin, Francesco Crea, et al.
Page
of 10